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A B S T R A C T
Background: Pertussis can lead to serious disease and even death in infants. Older adults are more vulnerable
to complications as well. In high-income countries, acellular pertussis vaccines are used for priming vaccina-
tion. In the administration of booster vaccinations to different age groups and target populations there is a
substantial between-country variation. We investigated the effect of age on the response to acellular pertus-
sis booster vaccination in three European countries.
Methods: This phase IV longitudinal intervention study performed in Finland, the Netherlands and the United
Kingdom between October 2017 and January 2019 compared the vaccine responses between healthy partici-
pants of four age groups: children (710y), adolescents (1115y), young adults (2034y), and older adults
(6070y). All participants received a three-component acellular pertussis vaccine. Serum IgG and IgA anti-
body concentrations to pertussis antigens at day 0, 28, and 1 year were measured with a multiplex immuno-
assay, using pertussis toxin concentrations at day 28 as primary outcome. This trial is registered with
ClinicalTrialsRegister.eu (2016003,67842).
Findings: Children (n = 109), adolescents (n = 121), young adults (n = 74), and older adults (n = 75) showed
high IgG antibody concentrations to pertussis toxin at day 28 with GMCs of 147 (95% CI 120181), 161 (95%
CI 132196), 103 (95% CI 80133), and 121 IU/ml (95% CI 94155), respectively. A significant increase in
GMCs for vaccine antigens in all age groups by 28 days was found which had decreased by 1 year. Differences
in patterns of IgG GMCs at 28 days and 1 year post-vaccination did not have a consistent relationship to age.
In contrast, IgA antibodies for all antigens increased with age at all timepoints.
Interpretation: Acellular pertussis booster vaccination induces significant serum IgG responses to pertussis
antigens across the age range which are not uniformly less in older adults. Acellular boosters could be consid-
ered for older adults to reduce the health and economic burden of pertussis.










Pertussis is an acute respiratory disease caused by the gram-
negative bacterium Bordetella pertussis [1]. It can lead to serious
disease and even death, especially in infants [2]. Complications
due to pertussis are also associated with patients with chronic dis-
eases and older age [3]. The incidence of clinical pertussis cases
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dropped with the introduction of whole cell (wP) pertussis vac-
cines in the 1940/1950s [4]. However, due to reported high reacto-
genicity rates and consequent decrease in vaccine coverage,
acellular pertussis (aP) vaccines were developed in the late 1970/
1980s. These vaccines proved to be less reactogenic and the short-
term efficacy seemed to be similar to wP vaccines [5,6]. However,
long-term efficacy of aP vaccines appeared to be inferior compared
with wP vaccines and natural infection although whole cell vac-
cines were reported to have a broad range of efficacy, some had
significantly lower efficacy than aP vaccines [68]. While natural
infection, acellular and whole cell vaccination all three induce
antibodies and protect against disease, the ability of aP vaccines to
protect against colonisation in comparison with wP vaccines or
natural infection seems limited. In the baboon model it has been
shown that natural infection and wP vaccination also protect
against newly acquired colonisation and consequent transmission
of B. pertussis. Therefore aP vaccines may be less effective than wP
vaccines in generating herd immunity [9].
The switch from wP to aP vaccines was made since 1990 in many
developed countries [6,1013]. Several aP vaccines are available:
two-component aP (aP2) vaccines contain pertussis toxin (Ptx) and
filamentous haemagglutinin (FHA), three-component aP (aP3) vac-
cines also contain pertactin (Prn) and five-component aP (aP5) vac-
cines additionally contain Fimbriae 2 and 3 (Fim2/3). The aP vaccines
have proven to induce high IgG antibody levels against the various
vaccine antigens that play an important role in protection against
pertussis [14,15]. Specific antibody levels against pertussis vary per
vaccine antigen and the lack of an internationally established corre-
late of protection makes the interpretation of the data challenging
[1619].
Despite high vaccination coverage of wP/aP vaccines, pertussis
has re-emerged worldwide, usually with cyclic outbreaks [20].
These cyclic outbreaks of pertussis occurred every three to four
years in Finland before the onset of aP vaccinations in 2005 [21].
Since 1996 a similar pattern was seen in the Netherlands with
cyclic outbreaks every three to five years. Introduction of aP vac-
cines seemed to disrupt this cyclic pattern in Finland, but also after
the introduction of aP vaccines in 2005, the Netherlands still faced
outbreaks in 2008, 2012, and 2014 (Fig. 1) [2224]. In the United
Kingdom (UK), a cyclic pattern was observed in the wP era despite
low incidence, and following the switch to aP in 2004, there was a
major outbreak in 2012 and since then a cyclical pattern of out-
breaks every three to four years [25,26]. Notification rates are
dependant on the use of diagnostics, reporting and ascertainment
per country and therefore do not reflect the real incidence num-
bers. In response to continued pertussis disease, many countries
have adopted an accelerated schedule of primary series vaccina-
tions and all western countries have implemented booster vacci-
nations in childhood [27,28]. In addition, some countries
introduced extra aP boosters for adolescents and adult target pop-
ulations, including pregnant women, military conscripts, health-
care workers, and older adults [2934].
From the pertussis incidence data in Europe, it can be deduced that
the proportion of the observed pertussis cases in young children is
rather constant over the years, while that of the adolescents is declining
and the proportion of cases in adults 30 years and older is rising [24].
These European trends in pertussis incidences are also seen for the
three individual countries involved in this study. In the study countries,
the pertussis vaccination coverage at around age one in 2017 was 94%
in the Netherlands and the UK, and 99% in Finland [35].
The aim of this study was to investigate the effect of age on aP
booster vaccination when administered in school aged children, ado-
lescents, and young and older adults. The study was performed in
three European countries with differences in vaccination schedules
and pertussis epidemiology which allowed additional investigation
of possible country-specific effects.
Research in context
Evidence before this study
Pertussis is a severe and life-threatening respiratory disease
caused by Bordetella pertussis. Unvaccinated or incomplete vacci-
nated infants aremost vulnerable to serious complications of per-
tussis, but older adults have a higher chance of complications and
hospitalisation as well. In most European countries the acellular
pertussis vaccine is used with different infant priming vaccina-
tion schedules and booster vaccinations at different ages. Despite
a high vaccination coverage in European countries, notification
rates are increasing indicating an increasing circulation of Borde-
tella pertussis. We searched PubMed for clinical trials and reviews
up to August 14, 2017, with no language restrictions, using the
search terms (older adults OR elderly) AND pertussis AND (vacci-
nation OR vaccine OR Tdap) in the title and/or abstract. This
search revealed that older adults do show a response to an acellu-
lar pertussis booster vaccination but did not yield any clinical tri-
als that investigated possible differences in immunogenicity
between older adults and other age groups who regularly
received booster vaccinations, like school aged children, adoles-
cents, and young adults. Therefore, we performed this prospec-
tive clinical trial, comparing four different age groups (children
710 years old, adolescents 1115 years old, young adults
2034 years old, and older adults 6070 years old) in three dif-
ferent countries (Finland, the Netherlands, and the United King-
dom)with different epidemiological and vaccination background.
Added value of this study
This phase IV longitudinal intervention study is conducted as a
multicentre trial in Finland, the Netherlands, and the UK and
compares the effect of an acellular pertussis booster vaccination
in four different age groups and three European countries. Here
we present the IgG and IgA immune responses directed against
the pertussis vaccine components of a Tdap-IPV booster vacci-
nation administered to children, adolescents, and young and
older adults with a follow-up to one year. Our study shows that
IgG responses to the pertussis vaccine antigens do not have a
consistent relationship to age up to one year post-vaccination
and thus that the influence of age, and vaccination and epide-
miological background on the IgG responses is limited. The IgA
responses on the other hand seem to be higher at baseline in
older adults, who also show greater increase upon vaccination
and thus age influences the IgA responses.
Implications of all the available evidence
This study emphasizes that despite considerable differences in
age, country-specific vaccination schedules and history, and
epidemiological background, the IgG responses on the three-
component acellular pertussis vaccine in older adults is not uni-
formly less compared to children, adolescents, and young
adults. The widespread circulation of B. pertussis in high-
income countries underscores the need for vigilant surveillance
of whooping cough. Maternal immunisation to prevent pertus-
sis in young infants at high risk for serious disease and death
has been implemented in many countries and has been found
highly effective from birth until the primary vaccinations.
Besides the young infants also older adults are at increased risk
of complications and hospitalisation due to whooping cough.
This study shows that a booster vaccination could be consid-
ered for older adults in order to prolong their protection and
reduce the epidemiological pressure on the circulation of per-
tussis in the population.
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2. Methods
2.1. Study design and participants
This phase IV longitudinal intervention study was conducted as a
multicentre trial in Finland, the Netherlands, and the UK. In all three
countries, children aged 710 years, adolescents aged 1115 years,
young adults aged 2034 years, and older adults aged 6070 years
old were recruited. Finnish children were informed at local schools in
Turku after permission was received from the school authorities.
Adult participants were recruited by information in the newspapers
and by University of Turku and Turku University Hospital web pages.
The Finnish arm of this study was conducted by the Department of
Microbiology and Immunology (University of Turku, Turku, Finland)
in Turku University Hospital. Dutch participants were recruited by
mail-outs to a sex balanced sample in the region of Hoofddorp,
attained via the Municipal Administration (adolescents, young adults,
and older adults) or through the NIP (children). The Dutch arm of the
study was conducted by the Spaarne Academy (Spaarne Hospital,
Hoofddorp, the Netherlands). In the UK, age appropriate participants
in the Oxford region, identified via National Health Service databases,
received mail-outs, also posters and media advertisings were used.
The UK arm of the study was conducted by the Oxford Vaccine Group
(University of Oxford, Oxford, UK). All participants should have been
healthy and vaccinated according to the country-specific NIPs, which
are presented in Supplementary Table 1. Most important exclusion
criteria were the presence of serious immune modulating illnesses,
previous administration of serum products, occurrence of serious
adverse events after previous vaccinations, pregnancy, and for adults
administration of pertussis containing vaccines in the last five years.
A full list of inclusion and exclusion criteria can be found in the Sup-
plementary Panel. All participants received a Tdap3-IPV vaccine
(BoostrixTM-IPV - GlaxoSmithKline (GSK), Wavre, Belgium) at base-
line. Serum samples were collected at day 0 and 28 (§ 4 days), and 1
year (§ 4 weeks) post-vaccination and subsequently stored at 20 °C
until analysis. As part of a broader set of immunological studies not
reported here additional samples were drawn at day 7 and day 14 in
all groups and day 1 in the 1115year age group. All laboratory anal-
yses were performed at a single laboratory in Bilthoven the Nether-
lands. This study was initiated by the IMI2 PERISCOPE Consortium
[36].
2.2. Ethics statement
This human clinical study was designed and conducted in accor-
dance with the provisions of the Declaration of Helsinki (1996) and
the International Conference on Harmonisation Guidelines for Good
Clinical Practice. The trial was registered at the EU Clinical Trial data-
base (EudraCT number 2016-003678-42) and was approved by the
Medical Research Ethics Committees United (MEC-U,
NL60807.100.17-R17.039) in the Netherlands, the South Central -
Hampshire B Research Ethics Committee (REC, 19/SC/0368) in the
UK, and the MREC UTU (ETMK Dnro: 129/1800/2017) in Finland.
Written informed consent was obtained from all adult participants,
and parents or legal guardian of minors, at the start of the study.
2.3. Serological analysis
Serum IgG concentrations against Ptx (GSK), FHA (SP), Prn (GSK),
and Fim2/3 (SP) were quantified in independent duplicate using the
Fig. 1. Notification rates from the ECDC Surveillance Atlas for pertussis. 2019 [24].
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fluorescent-bead-based multiplex immunoassay (MIA) as previously
described [3739], and serum IgA concentrations for the pertussis
antigens were measured. In brief, the conjugated fluorescent
microbeads were incubated with serum samples in two dilutions
(200 and 4000), a reference serum in a dilution series and control
sera, on each plate. The measurement of the IgG and IgA antibody
levels was performed with a Bioplex LX200 in combination with Bio-
Plex Manager 6.2 (Bio-Rad Laboratories). For IgG an in-house stan-
dard, calibrated on the Pertussis Antiserum (human) 1st WHO
International Standard (IS) was used to express IgG antibody concen-
trations in IU/ml. For IgA the Pertussis Antiserum (human) 1st WHO
IS itself was used. For each analyte, the MFI was converted to IU/ml
by interpolation from a five-parameter logistic standard curve. The
in-house standard reference for IgG-Fim2/3 was calibrated against
U.S. reference pertussis antiserum (human) lot 3 and arbitrarily set at
100 AU/ml as previously described [38], and for IgA-Fim2/3 the Per-
tussis Antiserum (human) 1st WHO IS was arbitrarily set at
100 AU/ml. The lower limits of quantification (LLOQs) for IgG were
0214 IU/ml for Ptx and 0092 AU/ml for Fim2/3. The LLOQs for IgA
were 0032 IU/ml for Ptx and FHA, 0021 IU/ml for Prn, and
0049 AU/ml for Fim2/3. For IgG-Ptx, 20 IU/ml was defined as arbi-
trary cut-off of protection against clinical disease [4042], and
100 IU/ml was defined to be indicative for a recent infection in
absence of a vaccination in the last few years [39]. All the Luminex
antibody data have been deposited in the central database of the
PERISCOPE Consortium and can be accessed by a request to the PERI-
SCOPE management team.
2.4. Outcomes
The primary outcome of the study is the specific Ptx-IgG serologi-
cal antibody level at 28 days after vaccination in the four age groups
of the three countries. Secondary outcomes are IgG levels at 0 and
28 days, and one year of Ptx (only day 0 and one year), FHA, Prn, and
Fim2/3, and pertussis-specific IgA levels at those timepoints for the
same antigens.
2.5. Statistical analysis
In each of the three countries the study aimed to include 36 chil-
dren aged 710 years, 36 adolescents aged 1115 years, 25 young
adults aged 2034 years, and 25 older adults aged 6070 years, with
equal distribution between aP and wP primed adolescents in early
infancy in the Netherlands and Finland. The large number in the
school children and adolescent groups also allowed sufficient addi-
tional samples to be collected at day 1, day 7 or day 14, for immuno-
logical end-points not reported here. Unlike adult participants not
each child could be bled at all timepoints. A sample size of 108 per
child cohort, across all countries was estimated to give 80% power to
detect a standardised difference in log-anti-Ptx-IgG at one month
post booster of 042 IU/ml between age cohorts, allowing 15% loss to
follow-up or sample loss. The data obtained from the participants in
each country will be combined and analysed per age cohort. From all
participants successful blood samples at day 0 and 28 should have
been taken, otherwise they could be replaced.
Concentrations below the LLOQ were replaced by LLOQ/2. For
each antibody and antigen combination a linear mixed model was fit-
ted to the log-transformed concentrations. A linear mixed model can
be considered as a generalisation of a paired t-test [43]. This model
describes the log geometric mean concentrations (GMCs) while
accounting for the longitudinal structure of the measurements. Time-
point of blood sampling and age group were included in the model as
a two-way interaction as fixed effects. Participant ID was included as
a random intercept in the model and by the random intercept the
baseline concentration of each participant was taken into account. An
additional analysis with country included in the model was
performed as a three-way interaction as fixed effects, to reveal differ-
ences within age groups between countries.
To explore the effect of previous vaccinations with or without Prn
and/or Fim2/3, children and adolescents were subdivided in a group
exclusively vaccinated with aP2 vaccines (without Prn and Fim2/3)
(n = 10), a group exclusively vaccinated with aP3 vaccines (with Prn,
without Fim2/3) (n = 7), a group at least three times vaccinated with
aP5 vaccines (with Prn and Fim2/3)(n = 65), and a group primed at
least three times with a wP vaccine (n = 41). A similar model, where
age group was replaced by vaccination group, was used to analyse
the differences between aP and wP priming background, and
between participants who previously received only aP2, only aP3, at
least three times aP5 or at least three times wP vaccines.
Overall significance of the fixed effect terms was assessed by a
type III ANOVA. GMCs and their corresponding 95% confidence inter-
vals (95% CI), as well as their mutual GMC ratios, corresponding 95%
CI and p-values were obtained by post hoc analysis using Sat-
terthwaite's method [44,45]. P-values were adjusted by applying the
Benjamini-Hochberg procedure for multiple comparisons, controlling
the false discovery rate [46]. Non-relevant comparisons were
excluded.
To investigate whether seasonal, diurnal or sex effects were pres-
ent, month (12-level categorical variable), hour (ten-level categorical
variable, based on quantiles), and sex (two-level categorical variable)
were included as fixed effects in the model as well. These, however,
were not significant and were excluded in further analyses.
All statistical analysis were done in R [47], using the lme4 package
[48], and lmerTest package [49].
2.6. Role of the funding source
The EFPIA partners from the PERISCOPE Consortium had some
input on the study design, e.g. the determination of the age of the
four groups of participants. They had no role in the data collection,
analysis, interpretation of the data, nor in the writing of the report.
The corresponding authors had full access to all data from the study,
and final responsibility for the decision to submit for publication was
by consensus of all co-authors.
3. Results
3.1. Participant and data overview
In Finland, participants were enroled in the study between August
2018 and January 2019. In total 123 study participants completed the
study, 36 children, 37 adolescents, 25 young adults, and 25 older
adults (Fig. 2). In the Netherlands, participants were enroled in the
study between October 2017 and March 2018. Since the distribution
between aP and wP primed adolescents was distorted, 12 extra par-
ticipants were enroled in October 2018. A total of 134 participants
completed the study subdivided in 36 children, 48 adolescents, 25
young adults, and 25 older adults (Fig. 2). In the UK participants were
enroled in the study between April 2018 and January 2019. A total of
117 participants completed the study, 36 children, 35 adolescents, 22
young adults, and 24 older adults (Fig. 2). Characteristics of all 379
participants (53% female) from whom serological data were available
and used for analyses, are shown in Table 1.
3.2. Pertussis-specific IgG concentrations per age at day 0
The baseline GMCs were low, though several significant differen-
ces between age groups were observed as summarised in Table 2.
The baseline GMCs of IgG-Ptx antibodies in all age groups were below
20 IU/ml, though six participants from the Netherlands, three from
Finland, and one from the UK showed antibody concentrations above
100 IU/ml suggestive of a recent infection (Fig. 3). Baseline IgG-Ptx
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and FHA GMCs in young adults (n = 74) were significantly lower than
in children (n = 109), adolescents (n = 120), and older adults (n = 75),
while this group had higher GMCs for Fim2/3 compared to the three
other age groups. Older adults showed a lower GMC for IgG-Ptx com-
pared to adolescents, a lower GMC for IgG-Prn but a higher GMC for
IgG-Fim2/3 compared to children.
3.3. Vaccine-specific IgG concentrations per age at day 28
The pertussis antigen specific GMCs 28 days after the Tdap-IPV
booster vaccination increased significantly in all age groups and for
all antigens except for Fim2/3 which antigen was not in the vaccine
(Table 2). For IgG-Ptx, the young adults (n = 74) still had the lowest
Fig. 2. Flow diagram BERT-study.
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GMC (103 IU/ml), significantly lower than children (n = 107) and ado-
lescents (n = 120) (147 and 161 IU/ml, respectively). In contrast
young adults had the highest GMC (331 IU/ml) for Prn which along
with the children and adolescents (293, 318 IU/ml respectively) was
significantly higher than the older adults (n = 75) (171 IU/ml).
3.4. Vaccine-specific IgG concentrations per age at one year
All pertussis antibody levels decreased significantly one year after
vaccination compared with levels at day 28, except for Fim2/3
(Table 2), but had remained significantly above baseline levels. The
group of young adults (n = 71) still had the lowest GMC for IgG-Ptx,
significantly lower than both paediatric groups. By comparison we
observed the highest GMC for IgG Prn in the young adults group, sig-
nificantly higher compared with the children (n = 106) and older
adults (n = 74). For both Ptx and FHA, children showed a lower anti-
body concentration compared with the adolescents (n = 120).
3.5. Pre- and post-vaccination IgA concentrations
In contrast to IgG antibodies the IgA antibodies to all pertussis
antigens tended to be higher with increasing age at day 0, day 28,
and at 1 year (Table 3). For IgA-Ptx and IgA-Prn, the fold increase
from day 0 to day 28 was also clearly age dependant (varying from 4-
fold for Ptx and Prn in children to 12-fold for Ptx and 21-fold for Prn
in older adults). The fold change decrease from day 28 to 1 year was
also slightly age dependant (varying from 13-fold for Ptx in children
to 23-fold for Prn in older adults). For FHA such a pattern could not
be observed.
3.6. Vaccine-specific antibody concentration differences between
countries
At baseline several country-specific differences could be observed
(Supplementary Table 2). Notable was the higher baseline IgG-FHA
GMC in Dutch older adults (n = 25) compared with the older adults
Table 1
Participant characteristics.
Characteristics Country No. of children aged
710 yrs [%]
No. of adolescents aged
1115 yrs [%]
No. of young adults aged
2034 yrs [%]
No. of older adults aged
6070 yrs [%]
No. of participants Total FI 37 37 25 25
NL 36 48 25 25
UK 36 36 24 25
Age in years Mean (95% CI) FI 90 (8793) 137 (132142) 302 (287317) 642 (632652)
NL 85 (8486) 136 (132139) 286 (270302) 659 (648670)
UK 92 (8996) 128 (125131) 261 (242280) 657 (645670)
Gender Female FI 18 [486] 19 [514] 21 [840] 21 [840]
NL 18 [500] 17 [354] 10 [400] 14 [560]
UK 16 [444] 18 [500] 16 [667] 13 [520]
Pertussis priming background aP FI 37 [1000] 19 [514] 0 [00] 0 [00]
NL 36 [1000] 25 [521] 0 [00] 0 [00]
UK 36 [1000] 36 [1000] 0 [00] 0 [00]
wP / unknown FI 0 [00] 18 [486] 25 [1000] 25 [1000]
NL 0 [00] 23 [479] 25 [1000] 25 [1000]
UK 0 [00] 0 [00] 24 [1000] 25 [1000]
FI: Finland; NL: Netherlands; UK: United Kingdom. CI: confidence interval.
Table 2
IgG GMCs per age group.
Antigen timepoint Children Adolescents Young adults Older adults
Ptx GMC (CI) in IU/ml Day 0 11 (914)a 14 (1218)a,b 4 (35)b,c,d 9 (712)a,d
Day 28 147 (120181)e 161 (132196)e 103 (80133)f,g 121 (94155)
1 year 35 (2843)h 49 (4059)i,j 26 (2034)h,k 43 (3456)j
FHA GMC (CI) in IU/ml Day 0 28 (2432)a 35 (3040)a 20 (1724)b,c,d 31 (2537)a
Day 28 290 (248340) 313 (269364) 299 (247361) 255 (211308)
1 year 88 (76104)h 121 (104141)i 113 (93137) 109 (90132)
Prn GMC (CI) in IU/ml Day 0 16 (1322)b 12 (1016) 13 (918) 8 (611)c
Day 28 293 (223386)l 318 (245414)l 331 (237463)l 171 (123239) e,f,g
1 year 85 (64111)j 114 (88149) 151 (108212)i,k 78 (56109)j
Fim2/3 GMC (CI) in AU/ml Day 0 21 (1529)a,b 33 (2444)a 80 (54120)b,c,d 40 (2759)a,c
Day 28 35 (2548)e 44 (3260)e 90 (60134)f,g,l 42 (2862)e
1 year 26 (1936)j 34 (2546)j 63 (4294)h,i 40 (2759)
Ptx: pertussis toxin; FHA: filamentous haemagglutinin; Prn: pertactin; Fim2/3: fimbriae 2 and 3; GMC: geometric mean concentra-
tion; CI: confidence interval; IU/ml: international units per millilitre; AU/ml: arbitrary units per millilitre. Significance per antigen
has been tested between age groups within a timepoint; p  005, p  001, p  0001. Significantly different from:
a young adults at day 0.
b older adults at day 0.
c children at day 0.
d adolescents at day 0.
e young adults at day 28.
f children at day 28.
g adolescents at day 28.
h adolescents at 1 year.
i children at 1 year.
j young adults at 1 year.
k older adults at 1 year.
l older adults at day 28.
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from Finland (n = 25) and the UK (n = 25). Also, IgG-Ptx is higher at
baseline in the Dutch older adults compared with their peers from
the UK. Children and adolescents in the Finnish groups showed sig-
nificantly higher baseline IgG-FHA GMCs compared with those
groups from the Netherlands and the UK but showed lower baseline
IgG-Prn and IgG-Fim2/3 levels.
At day 28 post-vaccination, country-specific differences were
observed in Dutch older adults who still showed a higher GMC for
IgG-FHA (425 IU/ml) than their peers in Finland and the UK (225 and
174 IU/ml, respectively) (Supplementary Table 2). The UK young
adults (n = 24) had a higher GMC for IgG-Prn compared with their
older adults. IgG-Ptx antibody concentrations below the arbitrary
Fig. 3. Individual IgG responses per age and country. Ptx: pertussis toxin; FHA: filamentous haemagglutinin; Prn: pertactin; Fim2/3: Fimbriae 2 and 3; IU/ml: international units per
millilitre; AU/ml: arbitrary units per mililitre. Ptx 20 IU/ml: arbitrary cut-off of protection; Ptx 100 IU/ml: indication of recent infection in absence of a recent vaccination. Values
below LLOQ are shown as 01 IU/ml or AU/ml. Concentrations from day 0, day 28 and 1 year connected per individual.
Table 3
IgA GMCs per age group.
Antigen timepoint Children Adolescents Young adults Older adults
Ptx GMC (CI) in IU/ml Day 0 028 (023035)a,b,c 046 (037057)c,d 06 (046078)c,d 101 (077131)a,b,d
Day 28 105 (084131)e,f,g 193 (156238)g,h 26 (19834) g,h 1216 (931591)e,f,h
1 year 078 (063097)i,j,k 129 (10516)k,l 171 (13225)k,l 543 (415711)i,j,l
FHA GMC (CI) in IU/ml Day 0 012 (008019)a,b,c 045 (03068)c,d 041 (02407)c,d 33 (196557)a,b,d
Day 28 217 (141335)e,f,g 549 (36383)f,g,h 1089 (6441842)e,g,h 9818 (581816569)e,f,h
1 year 025 (016039)i,j,k 129 (085196)k,l 245 (144416)k,l 2855 (16894828)i,j,l
Prn GMC (CI) in IU/ml Day 0 115 (08416)b,c 178 (13242)b,c 414 (279614)a,d 619 (417917)a,d
Day 28 462 (334639)e,f,g 877 (6431195)f,g,h 4555 (30696761)e,g,h 13196 (890219562)e,f,h
1 year 431 (313595)i,j,k 682 (499932)j,k,l 2092 (14043115)i,k,l 5721 (38558489)i,j
Fim2/3 GMC (CI) in AU/ml Day 0 105 (073151)a,b,c 225 (159318)b,c,d 73 (4671141)a,d 1014 (6491584)a,d
Day 28 179 (124257)f,g 278 (197393)f,g 864 (5521351)e,h 1317 (8432058)e,h
1 year 199 (139286)i,j,k 368 (259521)j,k,l 819 (5221284)i,l 1421 (9092222)i,l
Ptx: pertussis toxin; FHA: filamentous haemagglutinin; Prn: pertactin; Fim2/3: fimbriae 2 and 3; GMC: geometric mean concentration; CI: confidence interval;
IU/ml: international units per millilitre; AU/ml: arbitrary units per millilitre. Significance per antigen has been tested between age groups within a timepoint;
p  005, p  001, p  0001. Significantly different from:
a adolescents at day 0.
b young adults at day 0.
c older adults at day 0.
d children at day 0.
e adolescents at day 28.
f young adults at day 28.
g older adults at day 28.
h children at day 28.
i adolescents at 1 year.
j young adults at 1 year.
k older adults at 1 year.
l children at 1 year.
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cut-off of protection of 20 IU/ml were observed in two older adults
per country. This was also the case in four Dutch young adults and
one Dutch adolescent (Fig. 3).
One year post-vaccination most country-specific differences had
disappeared (Supplementary Table 2). In all age groups and in all
three countries 3 to 13 participants per group had antibody concen-
trations below the arbitrary protective cut-off of 20 IU/ml (Fig. 3).
IgA concentrations in older adults were generally highest in the
Netherlands, followed by Finland, and lowest in the UK at all three
timepoints and for all antigens (Fig. 4 and Supplementary Table 3).
3.7. Pertussis antibody concentrations in children and adolescents in
relation to vaccination background
When the results fromadolescents fromFinlandand theNetherlands
were divided in two groups, one group with wP (n = 41) and the other
withaP(n=44)primingvaccinehistory (Fig.5and6),nopre-orpost-vac-
cinationdifferencesbetweentheaPandwPgroupwereobservedagainst
Ptx, FHA, and Prn. The observed differences between Dutch and Finnish
aPprimedadolescents forIgG-Fim2/3andPrnwereinlinewiththediffer-
ent vaccination history regarding antigens included in the different aP
vaccines. The subanalyses between the different aP groups showed that
the aP2 group (n = 10) had lower IgG-Prn GMCs at all timepoints com-
pared with children and adolescents previously vaccinated with aP3
(n=7)andwPvaccines (n=41)(SupplementaryTable4). ForFim2/3asig-
nificant difference between aP3, aP5 (n = 65), andwPwas observed at all
timepoints, moreover, the aP3 group did not show a significant increase
and subsequent decrease, where the aP5 group did show this pattern
(SupplementaryTable5).
4. Discussion
Here we present the serological data after a Tdap-IPV booster vac-
cination in four age groups of three European countries. IgG
concentrations for all antigens demonstrated a booster pattern with
considerable increases of pertussis-specific antibodies observed in all
age groups after the first month. Although there were significant
decreases at one year the GMCs remained at least 3-fold higher than
baseline for all antigens and age groups. There were some significant
differences between age groups which varied by antigen but anti-
body responses were not consistently worse with increasing age.
These data emphasise that at least in terms of antibody quantity,
responses are not uniformly less in older adults compared with the
other age groups. When analysed with the countries separately, the
IgG antibody concentrations were overall not significantly different
in 90% (81/90 at 28 days) and 97% (87/90 at 1 year) of the compari-
sons. For IgA increases for all antigens were relatively smaller and
decreases varied in significance. Moreover, the IgA antibody concen-
trations showed pronounced increase with age for all antigens and
timepoints especially notable in older adults.
Age seemed to influence the specific IgA responses to vaccination.
It is already known that pre-vaccination IgA concentrations increase
with age [5052]. It is also previously described that greater IgA-
antibody increase due to vaccination is positively correlated to high
pre-vaccination concentrations [53]. In this study we see a similar
pattern of higher IgA-antibody concentrations at baseline with higher
age. One month post-vaccination a clear age dependant increase for
IgA-Ptx and Prn is observed. Interestingly the antibody decay of these
IgA antibodies was also age dependant, with greater fold decrease in
older age groups. IgG responses on the other hand did not show a
consistent relationship with age. In contrast a booster vaccine study
in the USA previously described higher post-vaccination IgG concen-
trations for Ptx in adolescents compared with adults until three years
post-vaccination. They hypothesized that this was either due to
greater immune responsiveness at adolescent age or due to a shorter
time interval since the paediatric vaccinations in the adolescents
compared to the adults [54]. The post-vaccination GMCs for IgG-Ptx
of young adults in our study was lower compared with the
Fig. 4. Individual IgA responses per age and country. Ptx: pertussis toxin; FHA: filamentous haemagglutinin; Prn: pertactin; Fim2/3: Fimbriae 2 and 3; IU/ml: international units per
millilitre; AU/ml: arbitrary units per mililitre. Values below LLOQs for are shown as 001 IU/ml or AU/ml. Concentrations from day 0, day 28 and 1 year connected per individual.
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adolescents, but the older adults on the other hand, had a signifi-
cantly higher GMC compared with young adults one year post-vacci-
nation. Therefore, with respect to IgG, we did not observe less or
better immune responsiveness, or a positive or negative effect with
more recent vaccinations. Although the fold increase and subsequent
fold decrease in IgG responses was greater than in IgA, the degree of
change in IgG responses did not seem to be influenced by age. Differ-
ences in antibody kinetics between specific IgG and IgA responses
can possibly be explained by the route of primary activation. Usually
specific IgA responses result after the person encounters B. pertussis
in life [55], and IgA production is therefore considered activated via
the mucosal route, while IgG production has mostly been parenter-
ally activated after vaccination in early infancy. It is plausible to
assume that these two routes lead to different kinetics [56]. Both IgG
and IgA responses will be boosted by revaccination and reinfection. It
is highly likely that constant circulation of B. pertussis in the popula-
tion makes that the number of encounters increase with age. There-
fore, our results imply that IgA antibody responses are more
influenced by this constant circulation than the IgG responses. This is
supported by the Dutch data, given that the circulation of B. pertussis
is higher in the Netherlands and the Dutch older adults had highest
IgA concentrations for all antigens at all timepoints. The difference in
IgA concentrations between young and older adults might not only
be explained by the amount of encounters, but also the route of pri-
mary and secondary activation is likely to influence the IgA response
since the older adults will not all have been primed by vaccination
but by natural infection and also later the natural boosting might
have had a more pronounced effect to IgA mediated immunity.
Based on the reported cases with pertussis the circulation of B.
pertussismight be different between the three countries participating
in this study. The notification rate (N/100,000, all ages) in the last
decade was highest in the Netherlands, followed by Finland, and low-
est numbers in the UK (Fig. 1) [24]. These differences in circulation
between the countries appear to be reflected in some findings in this
study. The Dutch older adults had a significantly higher IgG and IgA
baseline GMC for Ptx, and FHA compared with UK older adults, while
the GMC of older Finnish adults were in between these two. For FHA
this difference still exists one month post-vaccination. The effect of
pertussis circulation is probably best reflected in older adults, since
their vaccination history is comparable between the countries and
previous vaccinations were administered long ago or not at all. Addi-
tionally, in this study the number of recent pertussis infections
defined as  100 IU/ml for IgG-Ptx at baseline [39], were most
observed in the Dutch cohort, followed by the Finnish cohort, and
then the UK, which is also in line with the national notification rates.
Nevertheless, we should bear in mind that the notification rates in
Fig. 5. IgG concentrations of pertussis vaccine components per wP and aP background. Ptx: pertussis toxin; FHA: filamentous haemagglutinin; Prn: pertactin; Fim2/3: Fimbriae 2
and 3; IU/ml: international units per millilitre AU/ml: arbitrary units per mililitre; aP priming: participants received exclusively acellular pertussis components containing vaccines
in the primary series; wP priming: participants received exclusively whole cell pertussis containing vaccines in the primary series. values below LLOQ are shown as 01 IU/ml or
AU/ml. Significance has been tested at day 0, day 28 and 1 year between wP and aP priming.
P. Versteegen et al. / EBioMedicine 65 (2021) 103247 9
the European countries as illustrated on the ECDC website are fluctu-
ating heavily per country and are strongly dependant on the use of
diagnostic methods (PCR and/or serology) and the accuracy of the
pertussis surveillance system in each country. Thus the reports might
therefore not reflect the real incidence numbers. Seroepidemiological
studies could provide more information about the seroprevalence of
pertussis antibodies in the population and thereby on the degree of
circulation of the pathogen, but these studies have been performed
in only a few European countries [57,58].
Differences due to vaccination background, especially between
wP and aP priming were anticipated since higher responses in aP
primed 4-year-olds compared with their wP primed peers have been
described [38]. Two studies in children of respectively 9 years of age
and 11 and 12 years of age, on the other hand, described better
responses in wP primed individuals [59,60]. In this study however,
the two priming backgrounds did not reveal any differences in IgG
levels against the vaccine antigens pre- or post-vaccination, which
might be explained by the limited number of participants for the
comparison between wP and aP priming. Participants previously vac-
cinated with aP2 vaccines (and thus lacking Prn) show a significantly
lower baseline and a lower Prn antibody increase upon ‘booster’ vac-
cination, reflecting a more primary response to Prn compared with
participants previously aP3 or wP vaccinated who show a real
booster response (Supplementary Table 4) [61]. Participants
previously vaccinated with aP3 vaccines (and thus lacking Fim2/3)
had lower Fim2/3 concentrations at baseline and did not show a sig-
nificant increase where aP5 and wP primed participants did show a
significant increase although Fim2/3 was not even in the vaccine,
indicating polyclonal activation of non-vaccine antigens (Supplemen-
tary Table 5). Polyclonal activation of unrelated antigens to which the
donor was previously immunised has been observed before [62].
It is questionable if a booster vaccination induces sufficient per-
tussis antibody levels on the long term (i.e. five years) for protection
considering the decrease in pertussis antibody levels one year after
the booster vaccination found in this study. However Ward et al.
found a vaccine efficacy of 92% in adolescents and adults for 22
months, Z€oldi et al. found a decrease in pertussis notifications in
young adults due to military conscripts vaccination, and Liu et al.
found a protective effect in older adults even after five years
[29,63,64]. The study from Taranger et al. found a correlation
between the height of the post-vaccination antibody concentrations
and protection against pertussis in toddlers up to 33 months post-
vaccination [65]. The one month post-vaccination GMCs from our
groups correspond most with the GMCs of the toddler group that
developed mild pertussis disease within 33 months indicating that
our study population might be susceptible to contract mild pertussis
within three years after the booster vaccination. The implementation
of additional pertussis boosters in the (older) adults should be
Fig. 6. IgA concentrations of pertussis vaccine components per wP and aP background. Ptx: pertussis toxin; FHA: filamentous haemagglutinin; Prn: pertactin; Fim2/3: Fimbriae 2
and 3; IU/ml: international units per millilitre; AU/ml: arbitraty units per mililitre; aP priming: participants received exclusively acellular pertussis components containing vaccines
in the primary series; wP priming: participants received exclusively whole cell pertussis containing vaccines in the primary series. values below LLOQ are shown as 01 IU/ml or
AU/ml. Significance has been tested at day 0, day 28 and 1 year between aP and wP priming.
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discussed not only in the context of the persistence of antibody levels
on the long term but also on the epidemiological pertussis situation
in each individual country. Moreover, a systematic literature review
from Kandeil et al. states that the pertussis disease burden is consid-
erably underestimated in older adults. Older adults are more likely to
have (pulmonary) comorbidities and are therefore more prone to
serious complications and hospitalisation. With the ageing popula-
tion, health and economic burden of pertussis is expected to rise [3].
A strength of the study is that serological antibody results of all
participants could reliably be compared between the three countries
and the four age groups, since all antibody measurements were per-
formed in the same lab with a highly standardised and validated mul-
tiplex assay. In addition, 375 participants in total completed this
pertussis booster vaccination study based on inclusion of 2248 par-
ticipants per age group per country.
A limitation of the study is that the vaccination background of the
participants appeared to be quite divergent between countries and
even within countries, thereby making analysis based on vaccination
background quickly underpowered.
In conclusion, the participants from all four age groups in the
three countries responded well to the aP booster vaccination as mea-
sured after one month and one year. The influence of age and epide-
miological background of pertussis in the countries seems limited on
the IgG vaccine responses, however increasing age does seem to have
a positive effect on IgA responses. Therefore, acellular pertussis
booster vaccination might also be considered for older adults and
individuals with pulmonary morbidities in order to reduce the health
and economic burden of pertussis in the population.
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